1. Introduction {#sec1}
===============

Frequently climacteric complaints, especially vasomotor symptoms (hot flashes, sweatings) and vaginal dryness, are treated with hormone therapy (HT) \[[@B1], [@B2]\]. Comprehensive clinical studies in the 1990s (Women\'s Health Initiative Study (WHI) and Women\'s International Study of long Duration Oestrogen after Menopause (WISDOM)) have demonstrated, however, that women who were treated with hormone therapy for climacteric complaints for several years had a significantly increased risk of breast cancer, cardiovascular events, pulmonary embolism, and dementia compared to placebo \[[@B3]--[@B5]\]. Both patients as well as physicians have been looking for effective and safe alternatives \[[@B3], [@B6]\]. Different extracts from *Cimicifuga racemosa* (Black Cohosh, Traubensilberkerze) are clinically used for climacteric complaints \[[@B7]\]. The monograph for *Cimicifuga racemosa* by the Herbal Medicinal Product Committee (HMPC) of the European Medicines Agency (EMA) stipulates a clear therapeutic benefit for three specific extracts and confirms a positive benefit-risk profile \[[@B8]\]. The extract production with a proven pharmaceutical quality under GMP conditions is the prerequisite.

The rhizome of *Cimicifuga racemosa* with attached roots is harvested in fall after the fruit has ripened and is used fresh or in dried form. The rhizome of *Cimicifuga racemosa* contains cycloartenol-type triterpene glycosides (amongst others actein, cimicifugoside, cimiracemoside A, and 23-epi-26-deoxyactein) and phenylpropanoids such as hydroxycinnamic acids. Further ingredients include alkaloids, N-methylserotonin, starch, fatty acids, resin, and tannins \[[@B9]\]. The isoflavone formononetin, once described as an ingredient, could not be detected uniformly in newer studies of extracts of *Cimicifuga racemosa* \[[@B10], [@B11]\].

The evidence regarding the aggregate of the different types of *Cimicifuga racemosa* extracts available on the market has been evaluated rather differently by various reviews. In this context, the heterogeneity of the data \[[@B12]\], contradicting results \[[@B13]\] or the inconsistency of data \[[@B14]\] have been criticised. Problems arise from the fact that previous reviews included all types of *Cimicifuga* preparations, whether approved as medicinal products or other products (food supplements or individualized single preparations) and their use for most different indications, without any differentiation.

However, none of these reviews took into consideration the logical system of phytotherapy, which requires a differentiation by type of extract, pharmaceutical quality, and indication. Herbal extracts are multiple-substance mixtures with varying composition, depending on the extractant used and further distinctions specific for manufacture, harvest, or cultivation. This can lead to different efficacies \[[@B15]\].

In contrast to food supplements or dietary foods, state-of-the-art proof of quality, efficacy, and safety is mandatory for the registration of herbal medicinal products. Strict quality criteria are applied especially for herbal medicinal products in all areas starting with drug harvesting followed by production of extract and finished product to the point of stability testing \[[@B16]\]. Quality and quality control are essential factors, which guarantee a stable efficacy and safety. The standardization of the manufacturing processes and a multitude of quality control steps from seed to finished product are prerequisites for the reproducibility of efficacy and safety demonstrated in studies and warrant a consistently high and certified quality of the medicinal product to both therapist and user.

Consequently, a differentiated review, evaluated by type of extract, pharmaceutical quality, and indication, which meets the characteristics and corresponds to the logical system of phytotherapy, is imperative. This review, therefore, differentiates clearly between registered and standardized medicinal products, on the one hand, and not registered/unspecified products, on the other. By means of a systematic review and assessment of the available evidence \[[@B17]\], it differentiates and evaluates the efficacy and the safety of phytopharmaceuticals from *Cimicifuga racemosa* for the treatment of climacteric complaints.

2. Methodology {#sec2}
==============

2.1. Search Algorithm {#sec2.1}
---------------------

We searched the databases MEDLINE, BIOSIS, EMBASE, EMBASE Alert, and PubMed for clinical studies with *Cimicifuga racemosa*. Furthermore, our research was complemented by a manual search in the library of authors. Goal of the literature search was the identification of clinical studies exploring the efficacy (search 1: efficacy) and safety of *Cimicifuga racemosa*. In reference to safety, 3 searches were conducted in order to identify both studies with results regarding the general safety (frequency and severity of adverse effects) as well as studies investigating the safety in regard to estrogen-sensitive organs (breast, uterus) and the liver.

The search was executed via a free text search using keywords linked with AND/OR/NOT-operators as well as in combination with the corresponding keywords (e.g., Medical Subject Headings) of the corresponding database. Used keywords were *Cimicifuga racemosa*/Traubensilberkerze/black cohosh/*Actaea racemosa*, clinical trial/clinical study/klinische Studie, Review/meta analysis/Meta Analyse, efficacy/Wirksamkeit, side effect/Nebenwirkung/adverse reaction/adverse drug/adverse event/adverse effect/ADR/UAW/interaction/Interaktion/Wechselwirkung/safety/Sicherheit/toxicity/Toxizität/intoxication/Intoxikation/poison, breast/Brust/mamma/uterin/uterus/Gebärmutter/tumor/tumour/cancer/hormon/estrogen/Östrogen, Leber/liver/hepat, case report/Fallstudie.

In order to ensure the currentness of the evidence, the range of the publications was limited to the years 2000--2012.

2.2. Selection of Publications {#sec2.2}
------------------------------

The search results were preselected based on their titles and abstracts. Criteria for inclusion and exclusion were predetermined ([Table 1](#tab1){ref-type="table"}). References, which were considered potentially relevant, were then viewed as full text. The result of the first selection included all references, which suggested meeting the inclusion and exclusion criteria. A final assessment occurred after the full texts had been submitted to the secondary selection. If full texts were available, furthermore a supplemental manual search was performed within the bibliography of the publications.

The data obtained from the secondary selection of the included references were assessed and evaluated in summary based on their methodology and the quality of their studies.

2.3. Inclusion, Exclusion, and Stratification Criteria {#sec2.3}
------------------------------------------------------

For the assessment of the efficacy, this review only lists clinical studies in which women with neurovegetative and/or psychic climacteric complaints were treated with the investigated phyto-pharmaceutical for a minimum of 3 months. For a complete assessment of the evidence, the criterion "clinical study" included all types of studies (randomized/controlled, meta-analyses of randomized/controlled studies, open/controlled, open/uncontrolled, case-control studies, and epidemiological cohort studies). In reference to the safety assessment, the duration of treatment was not limited. In the controlled studies, the comparative interventions included placebo, hormone preparations/tibolone, fluoxetine, and different dosages of the study preparation as well as the comparison of a *Cimicifuga* mono-preparation versus a combination of the same extract with another active ingredient. For the assessment of the efficacy of interventions against climacteric complaints, placebo-controlled studies are essential. Therapy regimes with hormones/tibolone were also included as comparative intervention, since these are standard therapies for climacteric complaints. In recent years, effects of selective serotonin-reuptake inhibitors against vasomotor and psychic climacteric complaints have been described; therefore, this comparative intervention has also been included.

We did not conduct any explicit search on the effect (preclinical studies, mode of action). Secondary literature such as reviews, general surveys, comments, discussions, and conference presentations as well as the description of individual case reports/casuistics have been excluded. Clinical studies whose primary endpoint was outside the registered indication for *Cimicifuga racemosa* (such as bone metabolism, anxiety disorder, cognition, and tamoxifen-induced complaints) were not included in reference to the efficacy. In regard to the question whether *Cimicifuga racemosa* is a safe treatment option for breast cancer patients with climacteric complaints, studies conducted with these patients were included for assessment. Search results yielding studies with combined preparations containing more than two active ingredients were not included, since a definite attribution of efficacy and safety is not possible for multiple-substance-combinations.

Patient-relevant endpoints were the reduction of neurovegetative and/or psychic climacteric symptoms, the frequency and severity of adverse events, and the influence on breast/uterus/breast-cancer risk or laboratory values (such as gonadotropins, ovarian hormones, and liver function parameters). A change of the symptomatology was measured based on different scales such as the Kupperman Menopause Index (KMI), the Menopause Rating Scale (MRS), the Hamilton Depression Scale (HAMD), and frequency of symptoms or diverse scales on health-related quality of life. The selection was not limited to certain scales.

Only publications in English or German have been included in this systematic analysis.

A significant point of this review is the differentiation of results both by indication as well as by type of extract and the regulatory status. The results were sorted and reported accordingly.

3. Results {#sec3}
==========

3.1. Literature Search on the Efficacy {#sec3.1}
--------------------------------------

A total number of 105 references were identified. After reviewing abstracts and full publications, 86 search results were excluded in accordance with the inclusion and exclusion criteria ([Figure 1](#fig1){ref-type="fig"}).

19 full publications on a total of 18 clinical studies, which investigated the efficacy of *Cimicifuga racemosa* for natural climacteric complaints, remain.

3.2. Literature Search on Safety {#sec3.2}
--------------------------------

For the assessment of the safety of *Cimicifuga racemosa*, 3 individual literature searches (general safety, safety on estrogen-sensitive organs, and liver safety) were conducted. If one of those individual searches yielded references whose content matched one of the other individual searches, these were allocated accordingly.

### 3.2.1. Literature Search on General Safety {#sec3.2.1}

A total of 134 references were identified. According to the inclusion and exclusion criteria, 106 of these search results were excluded ([Figure 2(a)](#fig2){ref-type="fig"}). In the end, we had found 28 publications concerning the general safety of *Cimicifuga racemosa*. Furthermore, we found 1 additional publication, which however exclusively deals with general safety, in our search regarding the drug safety in estrogen-sensitive organs.

Additionally, 2 publications were related to questions of drug safety in the liver and another 7 publications to the safety on estrogen-sensitive organs. Six publications additionally involved aspects of safety both in the liver and estrogen-sensitive organs.

### 3.2.2. Literature Search Concerning Safety on Estrogen-Sensitive Tissue {#sec3.2.2}

A total of 83 references were identified. As per the inclusion and exclusion criteria, 69 references were excluded ([Figure 2(b)](#fig2){ref-type="fig"}). Fourteen publications concerning the safety of *Cimicifuga racemosa* in reference to estrogen-sensitive organs remained.

In addition, 4 of these publications also gathered data on general safety and 3 on the liver safety as well as general safety.

### 3.2.3. Literature Search Concerning Liver Safety {#sec3.2.3}

Of initially 125 references, 117 were excluded as per the inclusion and exclusion criteria ([Figure 2(c)](#fig2){ref-type="fig"}). Eight publications remained, of which 7 referred to clinical studies. Furthermore, we found one meta-analysis of randomized, controlled studies.

Two of the publications additionally contained data on the general safety. Four publications contained additional data both on the general safety and the safety on estrogen-sensitive organs.

3.3. Summary of the Results of the Literature Search {#sec3.3}
----------------------------------------------------

### 3.3.1. Efficacy {#sec3.3.1}

In total, 19 publications from 18 clinical studies have been identified, in which 10,284 patients were treated with *Cimicifuga racemosa* against natural climacteric complaints. Of these, in 15 clinical studies 10,121 patients (98.5%) were treated with a registered medicinal product, while in 3 studies a total of 163 patients (1.5%) was treated with *Cimicifuga*-products that had not been registered as medicinal products.

Concerning the special isopropanolic *Cimicifuga racemosa* extract (iCR), 9 original publications resulting from 9 clinical studies were found \[[@B18]--[@B26]\]. Two of these publications investigated the combination of iCR and St. John\'s Wort in comparison to the monotherapy with iCR \[[@B25]\] or placebo, respectively \[[@B26]\]. Both preparations are medicinal products registered in several countries. In these 9 studies, a total of 9,391 patients were treated with iCR, 6,126 patients with the monotherapy and 3,265 patients with the combination preparation. Thus, more than 91% of all patients treated in clinical studies with *Cimicifuga racemosa* received the iCR-extract.

Furthermore, 1 publication of a clinical study conducted with a combination of *Cimicifuga racemosa* and St. John\'s Wort, which is distributed in Korea as medicinal product, has been found \[[@B27]\]. In this study, 47 patients were treated with the preparation. The publication did not contain any information on the extractant.

Three publications on a total of 2 clinical studies could be identified for the ethanolic extract BNO 1055 \[[@B28]--[@B30]\]. This is a medicinal product that has been registered in several countries. In both studies together, a total of 420 patients (4% of all patients treated in clinical studies) were treated with the preparation.

Furthermore, 3 individual studies on different ethanolic extracts, which all have been registered as medicinal products, have been found. These include the extract Ze 450 (registered in Switzerland) \[[@B31]\], a standard extract for generics (Cr 99) \[[@B32]\], and a Turkish preparation \[[@B33]\]. In these studies, 120, 83, or 60 patients, respectively, were treated with the corresponding preparation.

Furthermore, 3 individual studies conducted with US-American *Cimicifuga* preparations without marketing authorisation as medicinal products have been identified. These concerned one preparation whose extractant was not mentioned \[[@B34]\], one ethanolic extract \[[@B35]\], and one ethanolic extract, which was exclusively used as study medication \[[@B36]\]. The brand name for the unspecified extract can be found among US-American *Cimicifuga* food supplements. In the individual studies, 61, 80, or 22 patients, respectively, were treated with the individual *Cimicifuga* preparations.

### 3.3.2. Safety {#sec3.3.2}

A total of 41 full publications have been identified, which are based on 35 clinical studies and one meta-analysis of 5 published randomized, controlled studies. The publications furthermore include 5 reanalyses of clinical studies with additional information. Twenty-five clinical studies as well as the meta-analysis concerned registered medicinal products, 10 studies concerned unregistered products or preparations with unknown regulatory status or unspecified preparations. Within the context of these clinical studies, safety-relevant aspects were studied in a total of 13,492 users of *Cimicifuga racemosa*. Among those, 11,961 patients (88.6%) received registered medicinal products, 1,531 patients (11.4%) used *Cimicifuga* preparations not registered as medicinal products or unspecified preparations.

Concerning the isopropanolic *Cimicifuga racemosa* extract (iCR), we retrieved a total of 19 publications \[[@B18]--[@B23], [@B25], [@B26], [@B37]--[@B47]\]. Two of these investigated the combination of iCR and St. John\'s Wort in comparison to monotherapy with iCR \[[@B25]\] or placebo \[[@B26]\], respectively. The 19 publications are based on 17 clinical studies and 1 meta-analysis of 5 randomized, controlled studies already identified through the search \[[@B37]\]. One publication covers the second analysis of mammogram findings from a clinical study and their comparison with the findings from a comparable patient cohort obtained within the context of a placebo-controlled study with hormone therapy and tibolone \[[@B38]\]. On the whole, 11,054 patients (81.9%) were treated in the clinical studies with iCR, 7,789 with the monopreparation and 3,265 with the combination.

For the Korean combination preparation from *Cimicifuga racemosa* and St. John\'s Wort, the publication we already identified for the aspect "efficacy" also delivers safety-relevant information \[[@B27]\].

Regarding the ethanolic extract BNO 1055, 6 publications have been identified, which are based on 4 clinical studies \[[@B28]--[@B30], [@B48]--[@B50]\]. In these studies, a total of 597 patients (4.4%) were treated with the preparation.

The 3 studies already identified in the efficacy search for other registered preparations with ethanolic extracts also covered safety aspects \[[@B31]--[@B33]\].

Ten clinical studies refer to (mostly US-American) products not registered as medicinal products. These include the 3 publications already identified in the efficacy search \[[@B34]--[@B36]\], which also described safety-relevant aspects. Regarding the study of Newton et al. \[[@B35]\], 2 second analyses have been published \[[@B51], [@B52]\]. Furthermore, 2 publications on ethanolic extracts have been identified \[[@B53], [@B54]\] as well as 5 publications on extracts whose extractant has not been specified \[[@B55]--[@B59]\].

In 2 publications found for the isopropanolic extract (iCR), some patients, in addition to those who were treated with iCR, were treated with extracts, which were not specified in detail \[[@B45], [@B46]\].

4. Discussion {#sec4}
=============

4.1. Answering the Question of Efficacy {#sec4.1}
---------------------------------------

Based on current, GCP-compliant studies and a clear separation by extracts and indications, today\'s response to the question of efficacy is highly differentiated.

When differentiating by regulatory status, it becomes obvious that all registered medicinal products containing *Cimicifuga racemosa* investigated in clinical studies uniformly demonstrate as a minimum exploratory evidence for their efficacy. In particular the isopropanolic extract (iCR) as monotherapy and in combination with St. John\'s Wort as well as the Korean *Cimicifuga*-St. John\'s Wort combination actually yielded confirmatory evidence for their efficacy. In contrast, US-American extracts, not registered as medicinal products, in the majority (2 out of 3 studies) could not yield any evidence for efficacy ([Table 2](#tab2){ref-type="table"}). Evidence for efficacy clearly and significantly depends on the regulatory status as medicinal product, when analyzing the totality of all studies as well as when only analyzing those studies designed for confirmatory evidence (Tables [3](#tab3){ref-type="table"}(a) and [3](#tab3){ref-type="table"}(b)).

As early as in the 1980s, several clinical studies investigated the efficacy and safety of the first *Cimicifuga* preparation introduced in Germany in 1956 (Remifemin) for the indication of climacteric neurovegetative complaints \[[@B60]\]. Although the studies were conducted in a time period prior to the introduction of good clinical practice- (GCP-) criteria and prior to the publication of the monograph for *Cimicifuga racemosa* by the German Commission E \[[@B61]\], the "old" study results are clearly confirmed by the results of the "new" GCP-compliant studies.

Only 2 extracts were investigated in several GCP-compliant clinical studies for their efficacy. These are the isopropanolic extract iCR (9 publications from 9 studies with a total of 9,391 patients) and the ethanolic extract BNO 1055 (3 publications from 2 studies with a total of 420 patients). For both extracts therefore not only Levels of Evidence but also Oxford Grades of Recommendation can be derived. For all other extracts only one individual publication each is available.

### 4.1.1. Medicinal Products with the Isopropanolic Extract (iCR) {#sec4.1.1}

The efficacy of the iCR extract has been proven by 4 randomized, controlled studies \[[@B18], [@B20], [@B21], [@B26]\] and is further supported by 2 controlled as well as 3 uncontrolled studies with proof of efficacy as primary objective \[[@B19], [@B22]--[@B25]\].

A significantly superior improvement of climacteric complaints was demonstrated in a total of 304 patients after 3 months of treatment with the standard dose of iCR (40 mg) versus placebo. The superiority was especially significant in women in menopausal transition, and the strongest effect could be achieved for vasomotor complaints \[[@B18]\]. In comparison to low-dose transdermal hormone therapy in a total of 64 women, a comparably strong, significant improvement of vasomotor complaints, anxiety and depression could be achieved after 3 months \[[@B21]\]. Furthermore, in 3 months of therapy, a strong, significant improvement in the Kupperman Menopause Index, comparable to tibolone, was achieved in 244 Asian women. Since the iCR extract in this investigation, however, had the better safety profile, it was superior to tibolone in the benefit-risk profile \[[@B20]\]. After 3 months of treatment with the iCR extract, responder rates reached approximately 70--80% \[[@B19], [@B20]\].

In addition to vasomotor symptoms, many menopausal women also suffer from psychic complaints such as nervousness, irritability, anxiety, restlessness, or depressive moods \[[@B62], [@B63]\]. In these patients especially, the combination of St. John\'s Wort and *Cimicifuga* extract has been successfully used in clinical practice for decades. These clinical experiences have been confirmed by controlled clinical studies. In a randomized, controlled study in 301 women, the combination of iCR and St. John\'s Wort was used for 4 months. In comparison to placebo, both the Menopause Rating Scale as well as the Hamilton Rating Scale for Depression improved significantly \[[@B26]\]. In a controlled study with 6,141 patients who were treated for 6 months (or 736 patients who were treated up to 12 months, resp.), the combination of iCR and St. John\'s Wort proved to be significantly more effective than the iCR-monotherapy for psychic climacteric complaints \[[@B25]\].

Two larger, uncontrolled studies, in which 502 or 2,016 women, respectively, were treated for 3 months, demonstrated significant improvements of the Kupperman Menopause Index, which were most pronounced for vasomotor complaints \[[@B22], [@B23]\]. Another, uncontrolled study in 122 patients demonstrated a significant increase in the quality of life after 3 months of treatment \[[@B24]\].

The randomized, controlled studies \[[@B18], [@B20], [@B21], [@B26]\] all qualify for an Oxford Level of Evidence 1b. Due to the consistent Level-1 data, a Grade of Recommendation A can be stated \[[@B17]\] ([Figure 3](#fig3){ref-type="fig"}).

### 4.1.2. Medicinal Products with the Ethanolic Extract BNO 1055 {#sec4.1.2}

Exploratory efficacy of this extract was demonstrated in a randomized, controlled study with a small case number, on which a reanalysis has been published \[[@B28], [@B29]\]. It has also been supported by a uncontrolled study \[[@B30]\].

In the controlled study with a total of 62 women, the improvement in the Menopause Rating Scale (MRS) for the ethanolic *Cimicifuga* extract was comparable to a hormone preparation versus placebo after 3 months. Due to the small case number (*n* = 20 in the *Cimicifuga* group), however, it just stayed below the level of significance. In the exploratory reanalysis, however, a significant superiority versus placebo in reference to daily sweats, waking at night, and the MRS-subscores *major climacteric complaints*, *somatic complaints,* and *mental score* could be demonstrated.

The uncontrolled study investigated the safety of the extract in the endometrium in 400 women for 12 months and also demonstrated a significant improvement of the Menopause Rating Scale II and the MRS II 4-week weighted score of hot flushes.

The controlled study of low quality yielded sufficient evidence for an Oxford Level of Evidence 2b. Due to the consistent Level-2 data, a Grade of Recommendation B may be postulated ([Figure 3](#fig3){ref-type="fig"}).

### 4.1.3. Further Extracts with Marketing Authorization as Medicinal Product {#sec4.1.3}

For 4 further *Cimicifuga* medicinal products (three mono preparations and one combination with St. John\'s Wort) each with one publication of a randomized, controlled study, confirmatory (combination preparation) or at least exploratory evidence (mono preparations) for their efficacy was demonstrated.

After 3 months of therapy in a total of 180 women, the ethanolic extract Ze 450 was significantly superior versus placebo in the Kupperman Menopause Index. Furthermore, a higher dosage proved to be more effective in comparison to the standard dose \[[@B31]\]. The ethanolic extract Cr 99 was able to demonstrate its superiority versus placebo in the Kupperman Menopause Index and in the weekly weighted score of hot flashes after a 3-month therapy in a total of 125 women. The superiority was only significant, however, in a subgroup of women who suffered from stronger complaints (KMI \> 20) at the beginning of the study \[[@B32]\]. An extract registered as a medicinal product in Turkey (ethanolic as per manufacturer\'s homepage) and the control substance fluoxetine demonstrated a significant improvement in the modified Kupperman Menopause Index, Beck\'s Depression Scale, and the RAND-36-QoL after 6 months in 120 patients. Concerning the improvement of the Kupperman Menopause Index and hot flashes as well as night sweats, the *Cimicifuga*-extract was significantly superior to fluoxetine. In the other scores, fluoxetine proved to be better. The quality of these studies allows to postulate a Level of Evidence 2b ([Figure 3](#fig3){ref-type="fig"}).

A Korean combination preparation from *Cimicifuga racemosa* and St. John\'s Wort yielded confirmatory evidence for its efficacy after 3 months of use: in comparison to placebo there was a significantly superior improvement in the Kupperman Menopause Index. A total of 89 women participated in this study. This study justifies a Level of Evidence 1b ([Figure 3](#fig3){ref-type="fig"}).

### 4.1.4. Other Extracts without Marketing Authorization as Medicinal Product {#sec4.1.4}

For 3 US-American *Cimicifuga* preparations without marketing authorization as medicinal product, a total of 2 randomized, controlled and 1 open, uncontrolled study could be identified. The dosage information in the publications does not always clearly indicate whether it refers to the amount of extract or drug.

A 5-arm randomized, controlled study was conducted for 12 months with an ethanolic extract in a total of 351 women. Hereby, no significant differences could be found between the *Cimicifuga* preparation (daily dosage 160 mg) and placebo \[[@B35]\] in reference to the vasomotor symptoms. A 4-arm randomized, controlled study in a total of 89 women demonstrated no significant improvement of the frequency of vasomotor complaints in comparison to placebo after 12 months of treatment for another ethanolic extract (daily dose 128 mg) \[[@B36]\]. Merely an open, uncontrolled study in 61 women could demonstrate a significant improvement of the Kupperman Menopause Index after 3 months of treatment in comparison to baseline \[[@B34]\].

The controlled studies yielded no evidence for the efficacy of the used *Cimicifuga*-preparations, which prior to their use had not been subject to any control by regulatory drug approval procedures.

4.2. Answering the Question of Safety {#sec4.2}
-------------------------------------

### 4.2.1. General Safety {#sec4.2.1}

Of the 41 publications identified in the literature search, 31 investigated aspects relevant for general safety ([Table 4](#tab4){ref-type="table"}). Uniformly and independently from their regulatory status, they demonstrated that extracts from *Cimicifuga racemosa* have a good to very good tolerability. Overall, no side effects were recorded, which go beyond the known side effects listed in the HMPC monograph \[[@B8]\]. The placebo-controlled studies demonstrated that in regard to frequency and severity of adverse effects, *Cimicifuga racemosa* does not significantly differ from treatment with placebo \[[@B18], [@B26], [@B28], [@B32], [@B35], [@B36]\]. As also described in the HMPC-monograph, there are no generally known drug interactions for *Cimicifuga racemosa* \[[@B8]\]. This has been confirmed by 2 studies which did not find any clinically relevant interaction with cytochrome P-isoenzymes or P-glycoprotein \[[@B55], [@B56]\].

The safety data for the *Cimicifuga racemosa* preparations investigated in clinical studies can be assessed uniformly and in general confirm the safety of the used preparations.

### 4.2.2. Safety in regard to Estrogen-Sensitive Tissue {#sec4.2.2}

Twenty two of the 41 publications investigated safety-relevant aspects under the therapy with *Cimicifuga racemosa* in reference to estrogen-sensitive tissues such as breast or uterus ([Table 4](#tab4){ref-type="table"}). Under treatment with *Cimicifuga racemosa*, no clinically relevant changes of hormonal parameters (e.g., estradiol, FSH, and LH) were detected (e.g., \[[@B19], [@B21], [@B27], [@B36], [@B40], [@B52]\]). The endometrium is neither influenced by *Cimicifuga racemosa* \[[@B20], [@B21], [@B28], [@B30], [@B36], [@B43]\]. Mammographic breast density, breast cell proliferation, or cell morphology in the nipple aspirate fluid neither changed under *Cimicifuga* treatment \[[@B30], [@B34], [@B36], [@B38], [@B43]\]. Some smaller studies in breast cancer patients also demonstrated good tolerability of *Cimicifuga racemosa* in these patients \[[@B39], [@B41], [@B44], [@B49]\]. Several large case-control studies investigated the influence of *Cimicifuga racemosa* on breast cancer risk. A publication found no association between the application of *Cimicifuga racemosa* and breast cancer risk \[[@B59]\]. A US-American study demonstrated that breast cancer risk was reduced in users of *Cimicifuga racemosa* \[[@B46]\]. A study supported by the German Cancer Aid (Deutsche Krebshilfe e.V.) with more than 9,900 participating women showed no increase in breast cancer risk by ethanolic *Cimicifuga racemosa* extracts. For the isopropanolic *Cimicifuga racemosa* extract, this investigation even demonstrated a reduction of breast cancer risk \[[@B45]\]. This result was independent of lifestyle factors, tumor histology and tumor receptor status, and a longer duration of use improved risk reduction. A pharmacoepidemiological cohort study was able to demonstrate a slight reduction in the risk of recurrence for the isopropanolic *Cimicifuga racemosa* extract (*n* = 1,102 compared to *n* = 17,759 not treated with iCR) \[[@B47]\].

The entirety of the data clearly contradicts the existence of any estrogenic effects of *Cimicifuga racemosa*, which had been suggested decades ago. Under therapy, no adverse effects are to be expected on "critical" estrogen-sensitive organs such as breast or uterus. Based on the study results therefore, climacteric complaints in patients with breast cancer in their medical history can be treated with extracts of *Cimicifuga racemosa*. The most recent HMPC-monograph \[[@B8]\] confirms this assumption, provided that the cancer treating physician knows about the *Cimicifuga* therapy.

### 4.2.3. Liver Safety {#sec4.2.3}

In 11 of 41 publications, liver function tests were performed and described prior to as well as during or at the end of the treatment with *Cimicifuga racemosa* extracts ([Table 4](#tab4){ref-type="table"}). On the whole, no clinically relevant changes of liver function tests became evident (e.g., \[[@B18], [@B20], [@B21], [@B32], [@B48], [@B50], [@B58]\]). Also within the context of all the studies, no liver damage was clinically observed as adverse event. Significant evidence is available for the isopropanolic extract in the form of a meta-analysis of 5 randomized, controlled studies, in which liver safety parameters were recorded \[[@B37]\]. None of these revealed significant differences nor indications of a negative influence onto liver functions. An increase in the dosage compared to the HMPC recommendation or an increased duration of use, respectively, also demonstrated no significant effects.

In contrast to the findings from clinical studies, there are individual case reports, which suspect *Cimicifuga racemosa* within the context of hepatotoxicity. These include reports on food supplements, which are not subject to the same strict quality controls as medicinal products. For food supplements, for instance, impurities and adulterations (such as using cheaper Asian *Cimicifuga* species) are known \[[@B64]\]. Therefore, the reported suspected cases of liver side effects in connection with food supplements cannot be applied to registered *Cimicifuga* medicinal products in general.

A first analysis of internationally published and reported cases was conducted by the European Medicines Agency in 2006. It did not yield any certain causality. In 4 of 42 cases known worldwide, the causality was assessed as possible or probable, respectively \[[@B65]\]. A reanalysis of these 4 questionable cases by means of a liver-specific, validated algorithm was able to exclude a causal connection, however \[[@B66]\]. After 2006, further case reports have become known, which have been evaluated by different groups of experts. Depending on the used algorithm, one receives different causality assessments. When using the liver-unspecific Naranjo scale, a causal connection seems possible \[[@B67]\]. If, however, the assessment is based on the use of a liver-specific, validated algorithm, there is hardly any to no evidence at all for a hepatotoxic potential of *Cimicifuga racemosa* \[[@B68]--[@B72]\]. Experts in the field of hepatology point out the shortcomings of the Naranjo-scale as being not liver-specific and not validated for hepatotoxicity. They demand to apply only liver-specific causality assessment methods which are validated for liver toxicity (e.g., the CIOMS scale) in suspected cases of herb-induced liver injury \[[@B73]\].

### 4.2.4. Extract-Specific Differences in the Safety Data {#sec4.2.4}

From extract to extract, differences have to be taken into consideration in regard to the number of included patients and objectives of the conducted studies.

Of all patients, who were monitored for side effects in clinical studies investigating any *Cimicifuga racemosa* preparation (*n* = 13,492), the majority were treated with registered medicinal products (*n* = 11,961). In 1,531 patients no registered medicinal products were used or the preparations were not specified sufficiently, in order to be able to conclude their regulatory status. Among the medicinal products, there were only 2 preparations, which were used in a variety of studies, the isopropanolic *Cimicifuga racemosa* extract (iCR) and the ethanolic extract BNO 1055.

By far, most patients treated in clinical studies with a medicinal product (*n* = 11,054) received the isopropanolic *Cimicifuga racemosa* extract (iCR) among which 736 were observed for adverse events for a period of 12 months. Thus, both as monotherapy as well as in combination with St. John\'s Wort, the iCR extract is the only *Cimicifuga* extract which fulfills the requirements of the EU guideline ICH-E1 (CPMP/ICH/375/95) for the permission of a long-term therapy. For this extract, the state of the evidence is the best: among the 17 publications there are not only several high-quality, randomized, and controlled studies, but also a homogenous meta-analysis of 5 randomized, controlled studies. The safety data for the iCR-extract therefore corresponds to an Oxford Level of Evidence 1a, and based on the consistent study results a Grade of Recommendation A can be stated ([Figure 4](#fig4){ref-type="fig"}).

The ethanolic extract BNO 1055 was administered in altogether 597 patients. Among the publications, there is 1 randomized, controlled study (with low case number and quality, of which 2 exploratory reanalyses have been published), 1 controlled study and two uncontrolled studies. The status of the safety data allows an Oxford Level of Evidence 2b and Grade of Recommendation B ([Figure 4](#fig4){ref-type="fig"}).

The status of the data of other medicinal products in regard to drug safety corresponds to Oxford Level of Evidence 2b, for the Korean *Cimicifuga*-St. John\'s Wort combination to Level of Evidence 1b ([Figure 4](#fig4){ref-type="fig"}).

The evidence for the preparations not registered as medicinal products varies, the Level of Evidence regarding safety has to be considered maximally 2b ([Figure 4](#fig4){ref-type="fig"}).

4.3. Benefit-Risk Profile of *Cimicifuga racemosa*-Extracts---Differences between Registered Medicinal Products and Extracts without Marketing Authorization as Medicinal Product {#sec4.3}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

While all *Cimicifuga racemosa* extracts used in clinical studies demonstrated a good to very good safety profile independently of their regulatory status, this is not the case in regard to efficacy. Here, only officially assessed, registered medicinal products yielded the proof of efficacy. All *Cimicifuga* medicinal products could at least prove exploratory efficacy for the registered indication of neurovegetative and psychic climacteric complaints, and the isopropanolic extract (iCR) and a Korean medicinal product additionally yielded confirmatory evidence. Consistent investigations have been conducted for the isopropanolic iCR-extract and the ethanolic BNO 1055 extract, so that for these extracts Grades of Recommendation can be determined (iCR: LOE 1b, GR A; BNO 1055: LOE 2b, GR B). Both extracts are contained in high-quality medicinal products, which were originally registered in Germany, but in the meantime have been registered internationally. For several products without marketing authorization and therefore without quality approval by regulatory authorities, quality deficiencies may be the reason for the deviating results regarding efficacy. Short descriptions of product quality cannot replace extensive product specifications of drug registration dossiers. The quality of a herbal medicinal product depends on optimally concerted procedures applied from herbal substance to the final product. Optimization of procedures and thereby product quality clearly benefits from decades of technical expertise. For example, the oldest herbal medicinal *Cimicifuga racemosa* product (marketed since 1956) is manufactured according to standardized procedures, which are part of the descriptions in drug registration dossiers. These are approved by regulatory authorities in a multitude of different countries, but not accessible to the public. Available data on this long-standing product is consistently positive.

It is important to differentiate between clinical trials with standardized registered herbal remedies whose pharmaceutical quality has been checked by regulatory authorities and clinical trials with other products.

5. Conclusion {#sec5}
=============

Ideally, therapeutic decisions should be based on consistent scientific evidence. Consistently positive data regarding efficacy and safety have clearly been demonstrated for the isopropanolic *Cimicifuga racemosa* extract (iCR) and the ethanolic extract (BNO 1055) in the treatment of natural climacteric complaints. A multitude of clinical studies including more than 11,000 patients has been identified for the iCR extract, which demonstrates not only a good safety profile but also consistent confirmatory evidence for efficacy. Several clinical trials including more than 500 patients were identified for the BNO 1055 extract, demonstrating a good safety profile and consistent exploratory evidence for efficacy. Both extracts are in compliance with the recent *Cimicifuga racemosa* monograph of the Herbal Medicinal Products Committee and the corresponding preparations are registered as herbal medicinal products in many countries in and outside Europe.

This is the first review of a herbal treatment option based on a differentiation by extract and indication and therefore meets the distinctive characteristics of phytotherapy. The evidence concerning efficacy is favorable and consistent only for those *Cimicifuga racemosa* products which hold a marketing authorization for the treatment of climacteric complaints.

Professor Dr. A.-M. Beer held a lecture at the Congress of the Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) in 2012, supported by the company Schaper & Brümmer. Dr. A. Neff declares no conflict of interests.
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###### 

Inclusion, exclusion, and stratification criteria for the identification of the literature for the evaluation of the efficacy and safety of *Cimicifuga racemosa*.

                                                                                                   Efficacy   General safety   Safety in estrogen-sensitive organs   Liver safety
  ------------------------------------------------------------------------------------------------ ---------- ---------------- ------------------------------------- --------------
  *Inclusion criteria*                                                                                                                                                
  \(1\) Medical application of Black Cohosh                                                        \+         \+               \+                                    \+
  \(2\) 3-month treatment period at a minimum                                                      \+                                                                 
  \(3\) Full publication of clinical studies                                                       \+         \+               \+                                    \+
  \(4\) Efficacy in natural climacteric complaints (neurovegetative, psychic)                      \+                                                                 
  \(5\) Occurrence and frequency of adverse events                                                            \+               \+                                    \+
  \(6\) Influence on hormone parameters, breast, and uterus                                                                    \+                                     
  \(7\) Influence on liver function parameters                                                                                                                       \+
                                                                                                                                                                     
  *Exclusion criteria*                                                                                                                                                
  \(1\) Preparations containing more than two ingredients                                          \+         \+               \+                                    \+
  \(2\) Medication-induced complaints (e.g., tamoxifen)                                            \+                                                                 
  \(3\) Use outside the registered indication (bone metabolism, anxiety disorder, and cognition)   \+         \+               \+                                    \+
  \(4\) Prevention, including tertiary prevention of sequelae                                      \+                                                                 
  \(5\) Publications in languages other than English/German                                        \+         \+               \+                                    \+
                                                                                                                                                                     
  *Stratification criteria*                                                                                                                                           
  \(1\) Sorting by type of extract                                                                 \+         \+               \+                                    \+
  \(2\) Differentiation between registered medicinal products versus other products                \+         \+               \+                                    \+

###### 

Clinical studies between 2000 and 2012 on the efficacy of *Cimicifuga racemosa* in neurovegetative and psychic climacteric complaints, differentiated by extract and regulatory status (registered medicinal product-not registered as medicinal product).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Extract DER; extractant/standardization; brand name; manufacturer                                                                                                                                             Regulatory status                                   First author, year of publication   Design                    Number of patients                                                                                                                                                                                                        Dose (*Cimicifuga*-drug/day or control/day); duration of application   Main results                                                                                                                                                                                                  Impact on evidence
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ----------------------------------- ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  Isopropanolic special extract (iCR) DER 6--11 : 1; 40% Isopropanol Remifemin; Schaper & Brümmer, Germany                                                                                                      Medicinal product (EU and outside EU)               Liske, 2002                         RCT                       76: standard dose\                                                                                                                                                                                                        39 mg\                                                                 Significant improvement of the KMI; responder rate (KMI \< 15) after 3 months approx. 70%; high dose during menopausal transition significantly superior; no influence on hormones and vaginal cytology       *⊕*
                                                                                                                                                                                                                                                                                                                                  76: high dose\                                                                                                                                                                                                            127 mg\                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                   \                                                                                                                                                                                                                        3 months (*n* = 152)\                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                   \                                                                                                                                                                                                                        up to 6 months\                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                   \                                                                                                                                                                                                                        (*n* = 149)\                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             \                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Osmers, 2005                                                                                                                                                                                                  RCT                                                 153: iCR\                           40 mg\                    Significant improvement of the MRS-total score versus placebo; strongest effect in vasomotor complaints (hot flushes, sweatings, and sleep disorders) and higher superiority during menopausal transition                 *⊕⊕*                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                    151: placebo\                       3 months\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Nappi, 2005                                                                                                                                                                                                   RCT                                                 32: iCR\                            40 mg\                    In both groups comparably strong, significant improvement of vasomotor complaints, anxiety, and depression; no influence of iCR on hormones, liver function, and endometrium                                              *⊕*                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                    32: HT (TTSE~2~)\                   25 *μ*g + Progesterone\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                     \                                  3 months\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                     \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Bai, 2007                                                                                                                                                                                                     RCT                                                 122: iCR\                           40 mg\                    Comparably strong, significant reduction of the KMI in both groups; with better safety of iCR: superiority of iCR in the benefit-risk ratio                                                                               *⊕⊕*                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                    122: tibolone\                      2.5 mg\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                     \                                  3 months\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Schmidt, 2005                                                                                                                                                                                                 ONC                                                 502                                 40 mg\                    Significant improvement of the modif. KMI, most pronounced reduction of hot flushes and sweatings                                                                                                                         *⊕*                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                        3 months\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Vermes, 2005                                                                                                                                                                                                  ONC                                                 2,016                               40 mg\                    Significant improvement of the KMI, strongest for hot flushes, sweatings, sleeping difficulties, and anxiety                                                                                                              *⊕*                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                        3 months\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Julia Molla, 2009                                                                                                                                                                                             ONC                                                 122                                 40 mg\                    Significant increase in quality of life (Cervantes-HR-QoL-Scale), especially in the domains menopause/health and psyche                                                                                                   *⊕*                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                        3 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Isopropanolic special extract (iCR) (see previously) with *Hypericum perforatum* extract; standardized to 1 mg triterpene glycosides and 0.25 mg total hypericin Remifemin plus; Schaper & Brümmer, Germany   Medicinal product (EU)                              Uebelhack, 2006                     RCT                       151: iCR + Hyp\                                                                                                                                                                                                           120 mg (week 1--8)\                                                    Significant superiority versus placebo in the improvement of MRS- and HAMD-Scores                                                                                                                             *⊕⊕*
                                                                                                                                                                                                                                                                                                                                  150: placebo\                                                                                                                                                                                                             60 mg (week 9--16)\                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                   \                                                                                                                                                                                                                        4 months\                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Briese, 2007                                                                                                                                                                                                  OC                                                  3,114: iCR + Hyp\                   60--120 mg\               In both groups, significant improvement of the MRS-total score and -subscore *Psyche*; for psychic complaints iCR + Hyp is significantly more effective than iCR monotherapy                                              *⊕⊕*                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                    3,027: iCR\                         40 mg\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                     \                                  6 months (*n* = 6,141)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                     \                                  up to 12 months\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                        (*n* = 736)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  No data on extractant and DER *Cimicifuga*-extract with *hypericum* extract, standardized to 1 mg terpene glycosides and 0.25 mg hypericin Gyno-plus; Jin-Yang Pharm, Korea                                   Medicinal product (Korea)                           Chung, 2007                         RCT                       47: CR + Hyp\                                                                                                                                                                                                             According to SPC\                                                      Significant superiority in the improvement of the KMI versus placebo; no influence on hormones and vaginal cytology; significant increase of HDL in the CR + Hyp-group                                        *⊕⊕*
                                                                                                                                                                                                                                                                                                                                  42: placebo                                                                                                                                                                                                               3 months                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ethanolic extract (CR BNO 1055) DER 5--10 : 1; 58% ethanol Klimadynon; Bionorica, Germany                                                                                                                     Medicinal product (EU and outside EU)               Wuttke, 2003                        RCT                       20: CR\                                                                                                                                                                                                                   40 mg\                                                                 CR: comparable improvement of the MRS score to CE and superiority versus placebo, however, not significant; CR without effects on the endometrium, positive influence on bone markers and vaginal cytology    *⊕*
                                                                                                                                                                                                                                                                                                                                  22: HT (CE)\                                                                                                                                                                                                              0.6 mg\                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                  20: placebo                                                                                                                                                                                                               3 months                                                                                                                                                                                                                                                                             

  Wuttke, 2006                                                                                                                                                                                                  RCT-Reana-lysis                                     See Wuttke, 2003                    See Wuttke, 2003          Exploratory reanalysis: significant superiority of CR versus placebo in regard to improvement of daily sweats, nightly waking, and MRS subscores *major climacteric complaints, somatic complaints*, and *mental score*   *⊕*                                                                                                                                                                                                                                                                                  

  Rauš, 2006                                                                                                                                                                                                    ONC                                                 400                                 40 mg\                    No influence on the endometrium; significant improvement of MRS II and MRS II 4-week weighted score of hot flushes                                                                                                        *⊕*                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                        12 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ethanolic extract (Cr 99) 4.5--8.5 : 1; 60% Ethanol *Cimicifuga* Generic, Klimadynon Uno; Kolkmann, Bionorica, Germany                                                                                        Medicinal product (EU)                              Frei-Kleiner, 2005                  RCT                       83: CR\                                                                                                                                                                                                                   42 mg\                                                                 Superiority versus placebo in KMI and weekly weighted score of hot flushes, which is significant in patients with baseline KMI \> 20                                                                          *⊕*
                                                                                                                                                                                                                                                                                                                                  44: placebo                                                                                                                                                                                                               3 months                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ethanolic extract No information on DER, 50% ethanol Remixin, Mikro-Gen, Turkey                                                                                                                               Medicinal product (Turkey)                          Oktem, 2007                         RCT                       60: CR\                                                                                                                                                                                                                   40 mg\                                                                 Significant improvement in modified KMI, Beck\'s Depression Scale, and RAND-36 QoL in both groups; CR: significant superiority versus Fluoxetine in KMI and monthly scores for hot flushes and night sweats   *⊕*
                                                                                                                                                                                                                                                                                                                                  60: Fluoxetine\                                                                                                                                                                                                           20 mg\                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            6 months                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ethanolic extract (Ze 450) DER 4.5--8.5 : 1; 60% ethanol Cimifemin; Zeller, Switzerland                                                                                                                       Medicinal product (Switzerland)                     Kaiser, 2008                        RCT                       60: standard dose\                                                                                                                                                                                                        40 mg\                                                                 CR: significant superiority versus placebo in KMI\                                                                                                                                                            *⊕*
                                                                                                                                                                                                                                                                                                                                  60: high dose\                                                                                                                                                                                                            80 mg\                                                                 high dose: significant superiority versus standard dose in KMI                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                  60: placebo                                                                                                                                                                                                               3 months                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ethanolic extract\                                                                                                                                                                                            No medicinal product (USA)                          Newton, 2006                        RCT                       80: CR\                                                                                                                                                                                                                   160 mg extract?\                                                       No significant differences between CR and placebo for vasomotor symptoms per day, symptom intensity, Wiklund Vasomotor Symptom Subscale Score                                                                 *⊖*
  No information on DER, 70% ethanol, 2.5% triterpene glycosides Pure World, USA                                                                                                                                                                                                                                                  76: Multibotanical\                                                                                                                                                                                                       200 mg + 9 further\                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                  79: Multibotanical + Soy\                                                                                                                                                                                                 ingredients\                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                  32: CEE + MPA\                                                                                                                                                                                                             \                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                  84: placebo                                                                                                                                                                                                               0.625 mg + 2.5 mg\                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            12 months                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ethanolic extract 20 : 1; 75% ethanol, standardized to 3.64 mg triterpene glycosides University of Illinois/National Institutes of Health, USA                                                                No medicinal product, only study medication (USA)   Geller, 2009                        RCT                       22: CR\                                                                                                                                                                                                                   128 mg\                                                                No significant improvement of the frequency of vasomotor complaints by CR versus placebo                                                                                                                      *⊖*
                                                                                                                                                                                                                                                                                                                                  22: red clover\                                                                                                                                                                                                           120/378 mg\                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                  23: CEE/MPA\                                                                                                                                                                                                              0.625/2.5 mg\                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                  22: placebo                                                                                                                                                                                                               12 months                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  No information on extractant and DER CimiPure 2.5%, Pure World, Inc., USA                                                                                                                                     No medicinal product, food supplement (USA)         Ruhlen, 2007                        ONC                       61                                                                                                                                                                                                                        80 mg extract?\                                                        Significant improvement of the KMI by CR, increase after wash out; no effects in serum estrogen markers, pS2, or cellular morphology of NAF                                                                   *⊕*
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            3 months plus 3 months wash out                                                                                                                                                                                                                                                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CE: conjugated estrogens; CEE: conjugated equine estrogens; CR: *Cimicifuga racemosa*; DER: drug-extract ratio; HAMD: Hamilton Rating Scale for Depression; HR-QoL: Health-Related Quality of Life; HT: hormone therapy; Hyp: *Hypericum perforatum*; iCR: isopropanolic *Cimicifuga racemosa* special extract; KMI: Kupperman Menopause Index; MPA: medroxy progesterone acetate; MRS: Menopause Rating Scale; NAF: nipple aspirate fluid; OC: open controlled; ONC: open noncontrolled; RAND-36 QoL: RAND-36 measure of Health-Related Quality of Life; pS2: pS2 gene; RCT: randomised controlled trial; SPC: summary of product characteristics; TTSE~2~: transdermal estradiol.

Impact on Evidence for efficacy: *⊕⊕*: confirmatory evidence; *⊕*: exploratory evidence; *⊖*: no evidence.

###### 

Evidence for efficacy depends on regulatory status.

###### 

\(a\)

  All studies             Registered herbal medicinal product   
  ----------------------- ------------------------------------- ---
  Evidence for efficacy                                          
   Yes                    15                                    1
   No                     0                                     2

*n* = number of studies, *P* = 0.0008 (Chi^2^-test).

###### 

\(b\)

  Subset of confirmatory studies   Registered herbal medicinal product   
  -------------------------------- ------------------------------------- ---
  Evidence for efficacy                                                   
   Yes                             5                                     0
   No                              0                                     2

*n* = number of studies, *P* = 0.008 (Chi^2^-test).

Registered = holding a marketing authorization.

###### 

Clinical studies between 2000 and 2012 on the safety of *Cimicifuga racemosa*, differentiated by extract and regulatory status (registered medicinal product-not registered as medicinal product).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Extract DER; extractant/standardization; brand name; manufacturer                                                                                                                                             Regulatory status                                   First author, year of publication           Design                         Number of patients                                                                                         Dose (*Cimicifuga*-drug/day or control/day); duration of application                                               General safety                                                                                                                                  Safety on estrogen sensitive organs                                                 Liver safety
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ------------------------------------------- ------------------------------ ---------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- -------------------------------------------
  Isopropanolic special extract (iCR) DER 6--11 : 1; 40% isopropanol Remifemin; Schaper & Brümmer, Germany                                                                                                       Medicinal product (within and outside EU)          Naser, 2011                                 M-A (from 5 RCTs)              1,117: iCR or\                                                                                             40--128 mg\                                                                                                                                                                                                                                                                                                                                            *↔*: AST, ALT, and GGT\
                                                                                                                                                                                                                                                                                                                                               iCR + Hyp                                                                                                  3--6 months                                                                                                                                                                                                                                                                                                                                            no evidence for hepatotoxicity

  Jacobson, 2001\                                                                                                                                                                                               RCT\                                                Breast cancer patients (partly with Tam)\   40 mg\                         Few serious AEs only in Tam patients                                                                       *↔*: FSH, LH                                                                                                                                                                                                                                                                                                                                           
   \                                                                                                                                                                                                             \                                                  42: iCR\                                    60 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                    43: placebo\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                     \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Liske, 2002\                                                                                                                                                                                                  RCT\                                                76: standard dose\                          39 mg\                         Good/very good tolerability in both groups (82--100%), no serious AEs,\                                    *↔*: E~2~, LH, FSH, PRL, SHBG, and vaginal cytology                                                                                                                                                                                                                                                                                                    
   \                                                                                                                                                                                                             \                                                  76: high dose\                              127 mg 3 months (*n* = 152)\   *↔*: routine biochemistry and haematology\                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                     \                                          to 6 months (*n* = 149)                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Osmers, 2005\                                                                                                                                                                                                 RCT\                                                153: iCR\                                   40 mg\                         AEs: no significant differences, no serious AEs                                                                                                                                                                               *↔*: AST, ALT, and GGT                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                    151: placebo\                               3 months\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Nappi, 2005\                                                                                                                                                                                                  RCT\                                                32: iCR\                                    40 mg\                         iCR:\                                                                                                      iCR:\                                                                                                              *↔*: AST, ALT                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                    32: HT (TTSE~2~)\                           25 *μ*g + progesterone\        *↔*: CORT, CHOL, TGL\                                                                                      *↔*: E~2~, FSH, LH, PRL, and endometrial thickness; no vaginal bleeding                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                     \                                          3 months\                      ↑: HDL\                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                               ↓: LDL                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Bai, 2007\                                                                                                                                                                                                    RCT\                                                122: iCR\                                   40 mg\                         iCR: significantly fewer AEs, no serious AEs,\                                                             iCR: no postmenopausal bleeding;\                                                                                  *↔*: AST, ALT, and GGT                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                    122: Tibolone\                              2.5 mg\                        *↔*: BW, haematology, blood chemistry, urinalysis, AP, and CRP\                                            *↔*: endometrial thickness                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                3 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  García-Pérez, 2009                                                                                                                                                                                            OC                                                  45: iCR\                                    40 mg\                         Good tolerability,\                                                                                        *↔*: E~2~, FSH, LH, and TEST                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                    37: untreated                               3 months                       *↔*: routine biochemistry, lipids, PTH\                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                               ↓: NTx\                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                               ↑: AP                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Isopropanolic special extract (iCR) DER 6--11 : 1; 40% isopropanol Remifemin; Schaper & Brümmer, Germany                                                                                                       Medicinal product (within and outside EU)          Pockaj, 2004                                ONC                            21 (13 with breast cancer)                                                                                 40 mg\                                                                                                             1 AE (joint pain)                                                                                                                               *↔* transcriptional-activation assay S. cerevisiae PL3                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                          4 weeks                                                                                                                                                                                                                                                                                                                                                

  Schmidt, 2005                                                                                                                                                                                                 ONC                                                 502                                         40 mg\                         Tolerability very good, no AEs\                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                3 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Vermes, 2005                                                                                                                                                                                                  ONC                                                 2,016                                       40 mg\                         12.1% AEs, specified by *n* = 35; mostly stiffening of extremities, gastric pain, and allergic reactions                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                3 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Lindén-Hirschberg, 2007                                                                                                                                                                                       ONC                                                 74                                          40 mg\                         No serious AEs\                                                                                            *↔*: mammographic breast density (visual assessment), breast cell proliferation, endometrial thickness, and SHBG                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                6 months                       *↔*: CHOL, TGL, and IGF-I                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Reame, 2008                                                                                                                                                                                                   ONC                                                 6                                           40 mg\                                                                                                                                    *↔*: spontaneous LH pulsatility                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                3 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Rostock, 2011                                                                                                                                                                                                 ONC                                                 50 with breast cancer and Tam               20--80 mg\                     Tolerability good/very good: 90%\                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                6 months                       AEs not linked to iCR but Tam                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Lundström, 2011                                                                                                                                                                                               ONC/RCT Reana-lysis                                 64: iCR\                                    40 mg\                                                                                                                                    For iCR:\                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                    43: E~2~/NETA\                              2 mg/1 mg\                                                                                                                                *↔*: mammographic breast density (digitized assessment)                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                    49: tibolone\                               2.5 mg\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                    53: placebo                                 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Rebbeck, 2007                                                                                                                                                                                                 C-C\                                                1,524 controls:\                            No data                                                                                                                                   iCR/CR:\                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                iCR                                                 76: CR or iCR\                                                                                                                                                                        ↓: risk for breast cancer                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                    949 breast cancer cases: 25: CR or iCR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Isopropanolic special extract (iCR) DER 6--11 : 1; 40% isopropanol Remifemin; Schaper & Brümmer, Germany                                                                                                       Medicinal product (within and outside EU)          Obi, 2009                                   C-C\                           6,646 controls:\                                                                                           No data                                                                                                                                                                                                                                                            iCR:\                                                                                
                                                                                                                                                                                                                                                                                                                iCR                            320: iCR\                                                                                                                                                                                                                                                                                                                                                                     ↓: risk for breast cancer\                                                          
                                                                                                                                                                                                                                                                                                                                               89: other CR\                                                                                                                                                                                                                                                                                                                                                                 other CR:\                                                                          
                                                                                                                                                                                                                                                                                                                                               3,257 breast cancer cases:\                                                                                                                                                                                                                                                                                                                                                   *↔* risk for breast cancer                                                          
                                                                                                                                                                                                                                                                                                                                               112: iCR\                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                               34: other CR                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Henneicke-von Zepelin, 2007                                                                                                                                                                                   COH                                                 18,861 breast cancer cases\                 No data\                                                                                                                                  iCR:\                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                    1,102: iCR                                  mean follow-up 4.6 years                                                                                                                  ↓: risk for breast cancer recurrences                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Isopropanolic special extract (iCR) (see previously) with *Hypericum perforatum* extract; standardized to 1 mg triterpene glycosides and 0.25 mg total hypericin Remifemin plus; Schaper & Brümmer, Germany   Medicinal product (EU)                              Uebelhack, 2006\                            RCT\                           151: iCR + Hyp\                                                                                            120 mg (Week 1--8)\                                                                                                AEs: no significant differences, no serious AEs,\                                                                                                                                                                                    
                                                                                                                                                                                                                                                                     \                                           \                             150: placebo\                                                                                              60 mg (Week 9--16)\                                                                                                *↔*: haematology, biochemical and hormonal parameters                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                \                                                                                                         4 months\                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Briese, 2007\                                                                                                                                                                                                 OC\                                                 3,114: iCR + Hyp\                           60--120 mg\                    0.16% possibly treatment related AEs, no serious AEs, excellent/good tolerability \>90--98%                                                                                                                                                                                                                                                                                                                                                                       
   \                                                                                                                                                                                                             \                                                  3,027: iCR\                                 40 mg\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   \                                                                                                                                                                                                             \                                                   \                                          6 months (*n* = 6,141)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                     \                                          up to 12 months (*n* = 736)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  No data on extractant and DER *Cimicifuga*-extract with *hypericum*-extract, standardized to 1 mg terpene glycosides and 0.25 mg hypericin Gyno-plus; Jin-Yang Pharm, Korea                                   Medicinal product\                                  Chung, 2007                                 RCT                            47: CR + Hyp\                                                                                              As per SPC\                                                                                                        CR:\                                                                                                                                            CR:\                                                                                
                                                                                                                                                                                                                (Korea)                                                                                                                        42: placebo                                                                                                3 months                                                                                                           *↔*: routine chemistry, CHOL, LDL, and TGL\                                                                                                     *↔*: E~2~, FSH, LH, VMI\                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ↑: HDL\                                                                                                                                         no uterine bleeding in patients with gynecological disorders                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             AEs: 8 patients (versus 6) with 3 (versus 2) drop outs                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ethanolic extract (CR BNO 1055) DER 5--10 : 1; 58% ethanol Klimadynon; Bionorica, Germany                                                                                                                     Medicinal product (EU and outside EU)               Wuttke, 2003                                RCT                            20: CR\                                                                                                    40 mg\                                                                                                             CR: AEs: no significant differences, no serious AEs\                                                                                            CR:\                                                                                 
                                                                                                                                                                                                                                                                                                                                               22: HT (CE)\                                                                                               0.6 mg\                                                                                                            ↑: TGL, AP\                                                                                                                                     *↔*: E~2~, FSH, LH, PROG, and endometrial thickness\                                
                                                                                                                                                                                                                                                                                                                                               20: placebo                                                                                                3 months                                                                                                           ↓: CrossLaps                                                                                                                                    ↑: VMI                                                                              

  Wuttke, 2006                                                                                                                                                                                                  RCT Reana-lysis                                     See Wuttke, 2003                            See Wuttke, 2003               CR: nonserious AEs in 6 patients\                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Wuttke, 2006                                                                                                                                                                                                  RCT Reana-lysis                                     See Wuttke, 2003                            See Wuttke, 2003               See Wuttke 2003; CR:\                                                                                      See Wuttke 2003; CR:\                                                                                              CR:\                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                               ↑: CHOL, HDL, and LDL\                                                                                     ↓: SHBG                                                                                                            *↔*: AST, ALT, and GGT                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                               *↔*: HR, BP, BW, CREA, urea, uric acid, PROT, Na, K, Ca, Fe, BILI, GLU, blood count, PTT, and INR                                                                                                                                                                                                                                                                                                                                                                 

  Hernández-Muñoz, 2003\                                                                                                                                                                                        OC\                                                 Breast cancer patients\                     20 mg + 40 mg\                 CR + Tam: 4 AEs; Tam: 7 AEs; no serious AEs                                                                                                                                                                                                                                                                                                                                                                                                                       
   \                                                                                                                                                                                                             \                                                  90: Tam + CR\                               20 mg\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   \                                                                                                                                                                                                             \                                                  46: Tam\                                    12 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                     \                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Rauš, 2006                                                                                                                                                                                                    ONC                                                 400                                         40 mg\                         *↔*: HR, BP, BW, CHOL, HDL, LDL, TGL, INR, GLU, uric acid, BILI, and GLU                                   *↔*: endometrial biopsy, endometrial thickness, mammographic breast density, E~2~, FSH, and LH                     *↔*: AST, ALT, and GGT                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                12 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Nasr, 2009                                                                                                                                                                                                    ONC                                                 87                                          40 mg\                         *↔*: BP, BW, BILI, ALB, AP, PT, and PTC                                                                                                                                                                                       *↔*: hepatic blood flow, AST, ALT, and GGT                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                12 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ethanolic extract (Cr 99) 4.5--8.5 : 1; 60% Ethanol *Cimicifuga*-Generic, Klimadyon Uno; Kolkmann, Germany                                                                                                    Medicinal product (EU)                              Frei-Kleiner, 2005                          RCT                            83: CR\                                                                                                    42 mg\                                                                                                             AEs: no significant differences; For CR:\                                                                                                       *↔*: vaginal karyopyknotic index                                                    *↔*: AST, ALT
                                                                                                                                                                                                                                                                                                                                               44: placebo                                                                                                3 months                                                                                                           *↔*: HB, AP, and CREA                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ethanolic extract No information on DER, 50% ethanol Remixin, Mikro-Gen, Turkey                                                                                                                               Medicinal product (Turkey)                          Oktem, 2007                                 RCT                            60: CR\                                                                                                    40 mg\                                                                                                             CR: significantly fewer AEs versus fluoxetine                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                               60: Fluoxetine\                                                                                            20 mg\                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                          6 months                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ethanolic extract (Ze 450) DER 4.5--8.5 : 1; 60% ethanol Cimifemin; Zeller, Switzerland                                                                                                                       Medicinal product (Switzerland)                     Kaiser, 2008                                RCT                            60: standard dose\                                                                                         40 mg\                                                                                                             CR: 8 mild AEs, without relation to dose; placebo: 6 mild AEs                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                               60: high dose\                                                                                             80 mg\                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                               60: placebo                                                                                                3 months                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ethanolic extract No information on DER, 70% ethanol, 2.5% triterpene glycosides Pure World, USA                                                                                                              No medicinal product (USA)                          Newton, 2006                                RCT                            80: CR\                                                                                                    160 mg extract?\                                                                                                   CR: significantly fewer menstrual complaints/breast discomfort versus CEE + MPA, no significant differences regarding other AEs in all groups                                                                                        
                                                                                                                                                                                                                                                                                                                                               76: Multibotanical\                                                                                        200 mg + 9 further\                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                               79: Multibotanical + Soy\                                                                                  ingredients\                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                               32: CEE + MPA\                                                                                              \                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                               84: placebo\                                                                                               0.625 mg + 2.5 mg\                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                \                                                                                                         12 months\                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                           \                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Spangler, 2007                                                                                                                                                                                                RCT Reana-lysis                                     See Newton, 2006                            See Newton, 2006               CR:\                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                               *↔*: CHOL, HDL, LDL, TGL, INS, GLU, and FIBR                                                                                                                                                                                                                                                                                                                                                                                                                      

  Reed, 2008                                                                                                                                                                                                    RCT Reana-lysis                                     See Newton, 2006                            See Newton, 2006                                                                                                                          CR:\                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                          *↔*:, E~2~, FSH, LH, SHBG, bleeding patterns, and VMI                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ethanolic extract 20 : 1; 75% ethanol, 64 mg/capsule standardized to 3.64 mg triterpene glycosides University of Illinois/National Institutes of Health, USA                                                  No medicinal product, pure study medication (USA)   Geller, 2009                                RCT                            22: CR\                                                                                                    128 mg\                                                                                                            CR: AEs no significant differences, no serious AEs\                                                                                             CR:\                                                                                CR:\
                                                                                                                                                                                                                                                                                                                                               22: red clover\                                                                                            120/378 mg\                                                                                                        *↔*: CHOL, HDL, LDL, DXA, PT, TSH, AP, blood count, urinalysis, and serum chemistry                                                             *↔*: E~1~, E~2~, FSH, LH, SHBG, TEST, TVU, PAP, endometrial biopsy, and mammogram   *↔*: AST, ALT
                                                                                                                                                                                                                                                                                                                                               23: CEE/MPA\                                                                                               0.625/2.5 mg\                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                               22: placebo                                                                                                12 months                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  No information on extractant and DER, 32 mg/capsule standardized to 5.6% triterpene glycosides University of Illinois/National Institutes of Health, USA                                                      No medicinal product, pure study medication (USA)   Amsterdam, 2009                             RCT                            15: CR\                                                                                                    32--64 mg\                                                                                                         AEs: no significant differences                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                               13: placebo                                                                                                12 weeks                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ethanolic extract No information on DER, 70% ethanol Pure World, USA                                                                                                                                          No medicinal product (USA)                          Johnson, 2003                               OC                             7                                                                                                          32/64/128 mg extract\                                                                                                                                                                                                                                                                                                                                  No mercapturate conjugates found in urine
                                                                                                                                                                                                                                                                                                                                                                                                                                                          single application                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  No information on extractant and DER CR-extract 1,090 mg, standardized to 0.9% triterpene glycosides Solaray, USA                                                                                             No medicinal product (USA)                          Gurley, 2005                                OC                             12 (6 women)                                                                                               2180 mg extract\                                                                                                   *↔*: CYP3A4/5, CYP 1A2, CYP2E1, and CYP2D6                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                          28 days                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  No information on extractant and DER CR-extract 20 mg, standardized to 2.5% triterpene glycosides Enzymatic Therapy, USA                                                                                      No medicinal product (USA)                          Gurley, 2006                                OC                             16 (8 women)                                                                                               40 mg extract?\                                                                                                    *↔*: p-gp                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                          14 days                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  No information on extractant and DER CimiPure 2.5% Pure World, Inc., USA                                                                                                                                      No medicinal product, food supplement (USA)         Ruhlen, 2007                                ONC                            61                                                                                                         80 mg extract?\                                                                                                                                                                                                                                                    *↔*: E~2~, FSH, LH, pS2, and cellular morphology in NAF                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                          3 months plus 3 months wash out                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  No information on extractant and DER, standardized to 2.5% actein no data, Italy                                                                                                                              No data (Italy)                                     Firenzuoli, 2011                            ONC                            107                                                                                                        500--1,000 mg extract?\                                                                                            Minor transient AEs in 9 patients\                                                                                                                                                                                                  *↔*: AST, ALT, and GGT
                                                                                                                                                                                                                                                                                                                                                                                                                                                          min. 12 months                                                                                                     *↔*: LEU, BILI, AP, ALB, and INR                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Ethanolic extract, No information on DER, 75% ethanol, 32 mg extract/capsule, standardized to 7% triterpene glycosides Pure World/Naturex, USA                                                                No medicinal product(USA)                           Van Breemen, 2010                           ONC                            15                                                                                                         32/64/128 mg extract\                                                                                              *↔*: GLU, AP, BILI, and TSH                                                                                                                     *↔*: E~1~, E~2~, FSH, LH, SHBG, and TEST                                            *↔*: AST, ALT, and GGT
                                                                                                                                                                                                                                                                                                                                                                                                                                                          Single application                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Different CR preparations USA                                                                                                                                                                                 No data (USA)                                       Brasky, 2010                                C-C                            880 breast cancer patients:\                                                                               No data                                                                                                                                                                                                                                                            CR not associated with breast cancer risk                                            
                                                                                                                                                                                                                                                                                                                                               21: CR\                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                               34,136 noncases:\                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                               964: CR                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AE: adverse effect; ALB: serum albumin; ALT: alanine aminotransferase; AP: alkaline phosphatase; AST: aspartate aminotransferase; BILI: total bilirubin; BP: blood pressure; BW: body weight; Ca: Calcium; C-C: case-control study; CE: conjugated estrogens; CEE: conjugated equine estrogens; CHOL: total cholesterol; COH: cohort study; CORT: cortisol; CR: *Cimicifuga racemosa*; CREA: creatinine; CrossLaps: C-terminal telopeptides of collagen type I; CRP: C-reactive protein; CYP: cytochrome P450; DER: drug-extract ratio; DXA: dual-energy X-ray absorptiometry; E~1~: estrone; EU: European Union; E~2~: 17*β*-estradiol; Fe: iron; FIBR: fibrinogen; FSH: follicle-stimulating hormone; GGT: *γ*-glutamyl transpeptidase; GLU: glucose; HB: hemoglobin; HDL: high-density lipoprotein cholesterol; HR: heart rate; HT: hormone therapy; Hyp: *Hypericum perforatum*; iCR: isopropanolic *Cimicifuga racemosa* special extract; IGF-I: insulin-like growth factor I; INR: international normalized ratio; INS: insulin; K: potassium; LDL: low-density lipoprotein cholesterol; LEU: total leukocyte count; LH: luteinizing hormone; M-A: meta-analysis; MPA: medroxyprogesterone acetate; Na: sodium; NAF: nipple aspirate fluid; NTx: N-telopeptide of type I collagen; OC: open controlled; ONC: open noncontrolled; PAP: Pap smear; p-gp: p-glycoprotein; PRL: prolactin; PROG: progesterone; PROT: total protein; pS2: pS2 gene; PT: prothrombin time; PTC: prothrombin concentration; PTH: parathyroid hormone; PTT: activated thromboplastin time; RCT: randomised controlled trial; SHBG: sex hormone-binding globulin; SPC: summary of product characteristics; Tam: tamoxifen; TEST: testosterone; TGL: triglycerides; TSH: thyroid-stimulating hormone; TTSE~2~: transdermal estradiol; TVU: transvaginal ultrasound; VMI: vaginal maturation index.

*↔*: No clinically relevant changes; ↑: increase; ↓: decrease.
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